Cytek Biosciences, Inc. — Director's Dealing 2023

May 20, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cytek Biosciences, Inc. (CTKB)
CIK: 0001831915
Period of Report: 2023-05-18

Reporting Person: Barnett Valerie (General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-05-18	Common Stock	M	2016	—	Acquired	22358	Direct
2023-05-18	Common Stock	F	786	$6.69	Disposed	21572	Direct
2023-05-18	Common Stock	M	2454	—	Acquired	24026	Direct
2023-05-18	Common Stock	F	956	$6.69	Disposed	23070	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-05-18	Restricted Stock Units	$	M	2016	Disposed		Common Stock (2016)	Direct
2023-05-18	Restricted Stock Units	$	M	2454	Disposed		Common Stock (2454)	Direct

Footnotes

F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

F2: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.

F3: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18.

F4: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested.